1037 (1037) Fair Value & Analysis

Technology · Market cap HK$311M

1 1037 1037 · HK

PriceHK$0.4400

Fair ValueHK$0.4300

Upside-2.3%

Quality62/100

Evidence: Low Range HK$0.2800 – HK$0.5300

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −29.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2210 – HK$1.26 · fair‑value band HK$0.2800 – HK$0.5300 · the HK$0.4400 price screens above the HK$0.4300 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1037 (1037) currently trades at HK$0.4400, while our model-based Fair Value estimate is HK$0.4300 — implying the stock looks roughly 2.3% overvalued today. We read business quality at 62/100 (solid quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1037 generated revenue of HK$465M at a net margin of 13.5%. Revenue grew 21.8% year over year. It earns a return on equity of 17.1%. The balance sheet holds a net cash position of HK$104M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$465M

Revenue growth (YoY) +21.8%

Net margin 13.5%

Return on equity 17.1%

Free cash flow −HK$67.1M FY2025

Operating margin 16.5%

More key figures

EPS growth (YoY) -10.2%

Net cash HK$104M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1037 reported revenue of HK$708M in FY2025 versus HK$596M in FY2021, a compound +4.4%/yr. Reported net income was −HK$14.6M in FY2025.

Revenue +4.4%/yr

FY21 HK$596M

FY22 HK$832M

FY23 HK$678M

FY24 HK$559M

FY25 HK$708M

Net income

FY21 HK$34.3M

FY22 HK$27.8M

FY23 −HK$16.8M

FY24 −HK$12.4M

FY25 −HK$14.6M

Is 1037 fairly valued? → Check now

Similar stocks

6 more Information Technology Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
International Business Machines Corporation IBM	$301.77	$153.91	-49%
Accenture plc ACN	$124.83	$250.14	+100%
Tata Consultancy Services Limited TCS	₹2,154	₹2,580	+20%
Infosys Limited INFY	₹1,144	₹1,305	+14%
Fujitsu Limited FJTSF	$18.78	$24.50	+30%
HCL Technologies Limited HCLTECH	₹1,131	₹2,568	+127%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1037 (1037) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.4300 versus a price of HK$0.4400 — about −2% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1037?

Our model-based fair value for 1037 is HK$0.4300 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4400.

What is the quality score of 1037?

1037 has a Quality Score of 62/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1037 (1037)?

1037 reported trailing-twelve-month revenue of about HK$465M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1037?

The net profit margin of 1037 is about 13.5%, meaning it keeps roughly 13.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.